Organogenesis Holdings Depreciation & Amortization Growth & History (ORGO)
Organogenesis Holdings's depreciation and amortization was $15.3M for fiscal 2025.
View full Organogenesis Holdings company overviewOrganogenesis Holdings annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $15.3M | $1.6M | +12.11% |
| 2024 | 2024-12-31 | $13.6M | $3.2M | +30.39% |
| 2023 | 2023-12-31 | $10.4M | $4.6M | +78.75% |
| 2022 | 2022-12-31 | $5.8M | −$4.9M | −45.53% |
| 2021 | 2021-12-31 | $10.7M | $2.5M | +31.13% |
| 2020 | 2020-12-31 | $8.2M | −$1.6M | −16.72% |
| 2019 | 2019-12-31 | $9.8M | $2.8M | +40.81% |
| 2018 | 2018-12-31 | $7.0M | $1.4M | +23.99% |
| 2017 | 2017-12-31 | $5.6M | −$1.7M | −23.10% |
| 2016 | 2016-12-31 | $7.3M | — | — |
Organogenesis Holdings quarterly depreciation and amortization
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.7M | −$66,000 | −1.77% |
| Q1 2026 | 2026-03-31 | $4.2M | $730,000 | +21.20% |
| Q4 2025 | 2025-12-31 | $7.0M | — | — |
| Q3 2025 | 2025-09-30 | $4.0M | $459,000 | +12.86% |
| Q2 2025 | 2025-06-30 | $3.7M | $368,000 | +10.93% |
| Q1 2025 | 2025-03-31 | $3.4M | $372,000 | +12.11% |
| Q3 2024 | 2024-09-30 | $3.6M | $1.0M | +40.33% |
| Q2 2024 | 2024-06-30 | $3.4M | $1.1M | +51.08% |
| Q1 2024 | 2024-03-31 | $3.1M | −$852,000 | −21.71% |
| Q3 2023 | 2023-09-30 | $2.5M | −$132,000 | −4.93% |
| Q2 2023 | 2023-06-30 | $2.2M | −$521,000 | −18.95% |
| Q1 2023 | 2023-03-31 | $3.9M | $1.4M | +52.80% |
| Q3 2022 | 2022-09-30 | $2.7M | −$501,000 | −15.77% |
| Q2 2022 | 2022-06-30 | $2.7M | $443,000 | +19.21% |
| Q1 2022 | 2022-03-31 | $2.6M | $315,000 | +13.98% |
| Q3 2021 | 2021-09-30 | $3.2M | $1.2M | +57.28% |
| Q2 2021 | 2021-06-30 | $2.3M | $599,000 | +35.09% |
| Q1 2021 | 2021-03-31 | $2.3M | $534,000 | +31.06% |
| Q3 2020 | 2020-09-30 | $2.0M | −$301,000 | −12.97% |
| Q2 2020 | 2020-06-30 | $1.7M | −$651,000 | −27.61% |
| Q1 2020 | 2020-03-31 | $1.7M | −$681,000 | −28.38% |
| Q3 2019 | 2019-09-30 | $2.3M | $542,000 | +30.47% |
| Q2 2019 | 2019-06-30 | $2.4M | $566,000 | +31.58% |
| Q1 2019 | 2019-03-31 | $2.4M | $611,000 | +34.15% |
| Q3 2018 | 2018-09-30 | $1.8M | — | — |
| Q2 2018 | 2018-06-30 | $1.8M | — | — |
| Q1 2018 | 2018-03-31 | $1.8M | — | — |
Organogenesis Holdings depreciation and amortization trends
Over the last five fiscal years, Organogenesis Holdings's depreciation and amortization increased from $8.2M to $15.3M, a change of $7.1M. The latest reported quarter, Q2 2026, shows $3.7M.
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Organogenesis Holdings source filings ↗